ResearchMoz added Latest Research Report titled ” Global Respiratory Drugs Market to 2022 – Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way ” to it’s Large Report database.
The Respiratory Therapy Area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.
The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=811827
However, over the past decade the treatment of respiratory disorders has developed significantly, as has the importance for novel therapies and targeted therapies. The approval of the products Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment options for CF. Another important entry was the first biologic drug – omalizumab – approved in 2014 for the treatment of severe asthma. The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.
Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are currently in active in development for respiratory disorders.
Read All Asthma Market Research Reports @ http://www.researchmoz.us/asthma-market-reports.html
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Epidemiology 10
2.2.1 Asthma 11
2.2.2 Chronic Obstructive Pulmonary Fibrosis 12
2.2.3 Idiopathic Pulmonary Fibrosis 13
2.2.4 Cystic Fibrosis 14
2.3 Pathophysiology 15
2.3.1 Asthma 15
2.3.2 Chronic Obstructive Pulmonary Disease 17
2.3.3 Idiopathic Pulmonary Fibrosis 18
2.3.4 Cystic Fibrosis 20
2.4 Symptoms 21
2.5 Diagnosis 22
2.5.1 Asthma 22
2.5.2 Chronic Obstructive Pulmonary Fibrosis 22
2.5.3 Idiopathic Pulmonary Fibrosis 23
2.5.4 Cystic Fibrosis 24
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States – 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/